Last reviewed · How we verify
LP-168 tablet
At a glance
| Generic name | LP-168 tablet |
|---|---|
| Also known as | NWP-775, NWP-775 Placebo |
| Sponsor | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma (PHASE2)
- A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma (PHASE1)
- A Food Effect Study of LP-168 Tablets in Healthy Subjects (PHASE1)
- A Study of LP-168 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LP-168 tablet CI brief — competitive landscape report
- LP-168 tablet updates RSS · CI watch RSS
- Guangzhou Lupeng Pharmaceutical Company LTD. portfolio CI